Regeneron Announces Expected $102 Million IPR&D Charge for Q1 2026

On April 8, 2026, Regeneron Pharmaceuticals, Inc. announced preliminary financial expectations for the first quarter of 2026. The company expects to record an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis. This charge is primarily attributed to premiums paid on equity securities, as well as development milestone and up-front payments related to various collaboration and licensing agreements. Regeneron anticipates that this IPR&D charge will negatively impact both its GAAP and non-GAAP net income per diluted share by approximately $0.81 for the quarter. The company noted that these figures are preliminary and subject to final financial statement closing procedures. Regeneron typically does not forecast acquired IPR&D charges due to the inherent uncertainty regarding the timing and magnitude of such transactions. The filing emphasizes that these non-GAAP measures are intended to supplement, not replace, GAAP financial results.